Supreme Court Gene Patent Decision: What It Means For You

Last week, the US Supreme Court ruled on a significant gene patenting case.  The issue before the Court was whether or not a company’s patents on the BRCA1 and BRCA2 genes could be upheld. The landmark ruling states that a gene is a naturally occurring product of nature, and therefore cannot be patented. The Supreme Court’s ruling has important implications for clinicians, cancer patients, and individuals who are at higher risk of a BRCA mutation than the average population either by personal or family history. Many say that the Court’s ruling will increase access to genetic testing by eliminating the monopoly on the test, which will thereby reduce the cost of testing significantly and allow for consumer choice.  For many years, the American College of Medical Genetics has asserted that gene patents “stand firmly in the way of good patient care, interfere with informed decision-making by patients, impede training of the next generation of lab professionals and restrict the flow of information that is critical to advancing medical knowledge and better medical care accessible to all.”  Therefore, some anticipate that this decision will better enable appropriate and more affordable testing, particularly for those who are uninsured or underinsured. 
 
Carrie Horton, MS, CGC
Director of Genetic Counseling
West Clinic
 
Brad Somer, MD
Medical Oncology
West Clinic

Post new comment

The content of this field is kept private and will not be shown publicly.
Image CAPTCHA
Enter the characters shown in the image.
By submitting this form, you accept the Mollom privacy policy.
Placeholder for AddThis